Pulmonary vascular and right ventricular dysfunction in adult critical care: Current and emerging options for management: A systematic literature review

Critical Care

Volumn 14, Issue 5, 2010, Pages

  Price, Laura C ^a   Wort, Stephen J ^a   Finney, Simon J ^a   Marino, Philip S ^a   Brett, Stephen J ^b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; BOSENTAN; DOBUTAMINE; DOPAMINE; HYPERTENSIVE FACTOR; ILOPROST; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; NITRIC OXIDE; NORADRENALIN; PHOSPHODIESTERASE III INHIBITOR; PROSTACYCLIN; SILDENAFIL; VASODILATOR AGENT; VASOPRESSIN; ANTIHYPERTENSIVE AGENT; VASOCONSTRICTOR AGENT;

ARTICLE; AUTONOMIC DYSFUNCTION; BRADYCARDIA; BRONCHOSPASM; COUNTERPULSATION; DEVICE; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; EDEMA; EPISTAXIS; EXTRACORPOREAL CIRCULATION; HEADACHE; HEART AFTERLOAD; HEART ARRHYTHMIA; HEART ASSIST DEVICE; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART SURGERY; HOT FLUSH; HUMAN; HYPOTENSION; HYPOXEMIA; INTENSIVE CARE; ISCHEMIC OPTIC NEUROPATHY; JAW PAIN; LIVER FUNCTION TEST; LOW DRUG DOSE; LUNG VASCULAR RESISTANCE; METHEMOGLOBINEMIA; NAUSEA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; RISK BENEFIT ANALYSIS; SEPTIC SHOCK; SHOCK; SIDE EFFECT; SYNCOPE; SYSTEMATIC REVIEW; THORAX PAIN; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR; VASODILATATION; ADULT; DISEASE MANAGEMENT; DRUG EFFECT; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; VASCULAR RESISTANCE;

ADULT; ANTIHYPERTENSIVE AGENTS; CRITICAL CARE; DISEASE MANAGEMENT; HUMANS; HYPERTENSION, PULMONARY; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 77956671273     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9264     Document Type: Article

References (365)

1. Snow RL, Davies P, Pontoppidan H, Zapol WM, Reid L. Pulmonary vascular remodeling in adult respiratory distress syndrome. Am Rev Respir Dis 1982, 126:887-892.
2. Gillis CN, Pitt BR, Wiedemann HP, Hammond GL. Depressed prostaglandin E1 and 5-hydroxytryptamine removal in patients with adult respiratory distress syndrome. Am Rev Respir Dis 1986, 134:739-744.
3. Greene R, Zapol WM, Snider MT, Reid L, Snow R, O'Connell RS, Novelline RA. Early bedside detection of pulmonary vascular occlusion during acute respiratory failure. Am Rev Respir Dis 1981, 124:593-601.
4. Piazza G, Goldhaber SZ. The acutely decompensated right ventricle: pathways for diagnosis and management. Chest 2005, 128:1836-1852. 10.1378/chest.128.3.1836, 16162794.
5. Jacobs AK, Leopold JA, Bates E, Mendes LA, Sleeper LA, White H, Davidoff R, Boland J, Modur S, Forman R, Hochman JS. Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. J Am Coll Cardiol 2003, 41:1273-1279. 10.1016/S0735-1097(03)00120-7, 12706920.
6. Kimchi A, Ellrodt AG, Berman DS, Riedinger MS, Swan HJ, Murata GH. Right ventricular performance in septic shock: a combined radionuclide and hemodynamic study. J Am Coll Cardiol 1984, 4:945-951. 10.1016/S0735-1097(84)80055-8, 6491086.
7. Parker MM, McCarthy KE, Ognibene FP, Parrillo JE. Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest 1990, 97:126-131. 10.1378/chest.97.1.126, 2295231.
8. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997, 336:111-117. 10.1056/NEJM199701093360207, 8988890.
9. Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985, 6:359-365. 10.1016/S0735-1097(85)80172-8, 4019921.
10. Dabestani A, Mahan G, Gardin JM, Takenaka K, Burn C, Allfie A, Henry WL. Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography. Am J Cardiol 1987, 59:662-668. 10.1016/0002-9149(87)91189-1, 3825910.
11. Bossone E, Bodini BD, Mazza A, Allegra L. Pulmonary arterial hypertension: the key role of echocardiography. Chest 2005, 127:1836-1843. 10.1378/chest.127.5.1836, 15888866.
12. Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, Chamera E, Corretti MC, Champion HC, Abraham TP, Girgis RE, Hassoun PM. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006, 174:1034-1041. 10.1164/rccm.200604-547OC, 16888289.
13. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463. 10.1016/j.echo.2005.10.005, 16376782.
14. Le Tulzo Y, Seguin P, Gacouin A, Camus C, Suprin E, Jouannic I, Thomas R. Effects of epinephrine on right ventricular function in patients with severe septic shock and right ventricular failure: a preliminary descriptive study. Intensive Care Med 1997, 23:664-670. 10.1007/s001340050391, 9255647.
15. Vieillard-Baron A, Prin S, Chergui K, Dubourg O, Jardin F. Echo-Doppler demonstration of acute cor pulmonale at the bedside in the medical intensive care unit. Am J Respir Crit Care Med 2002, 166:1310-1319. 10.1164/rccm.200202-146CC, 12421740.
16. Jardin F, Dubourg O, Bourdarias JP. Echocardiographic pattern of acute cor pulmonale. Chest 1997, 111:209-217. 10.1378/chest.111.1.209, 8996019.
17. Fischer LG, Van Aken H, Burkle H. Management of pulmonary hypertension: physiological and pharmacological considerations for anesthesiologists. Anesth Analg 2003, 96:1603-1616. 10.1213/01.ANE.0000062523.67426.0B, 12760982.
18. Ocal A, Kiris I, Erdinc M, Peker O, Yavuz T, Ibrisim E. Efficiency of prostacyclin in the treatment of protamine-mediated right ventricular failure and acute pulmonary hypertension. Tohoku J Exp Med 2005, 207:51-58. 10.1620/tjem.207.51, 16082155.
19. Sibbald WJ, Paterson NA, Holliday RL, Anderson RA, Lobb TR, Duff JH. Pulmonary hypertension in sepsis: measurement by the pulmonary arterial diastolic-pulmonary wedge pressure gradient and the influence of passive and active factors. Chest 1978, 73:583-591. 10.1378/chest.73.5.583, 648208.
20. Wort SJ, Evans TW. The role of the endothelium in modulating vascular control in sepsis and related conditions. Br Med Bull 1999, 55:30-48. 10.1258/0007142991902286, 10695078.
21. Albertini M, Clement MG, Hussain SN. Role of endothelin ETA receptors in sepsis-induced mortality, vascular leakage, and tissue injury in rats. Eur J Pharmacol 2003, 474:129-135. 10.1016/S0014-2999(03)02037-5, 12909204.
22. Rossi P, Persson B, Boels PJ, Arner A, Weitzberg E, Oldner A. Endotoxemic pulmonary hypertension is largely mediated by endothelin-induced venous constriction. Intensive Care Med 2008, 34:873-880. 10.1007/s00134-007-0980-9, 18214440.
23. Osman D, Monnet X, Castelain V, Anguel N, Warszawski J, Teboul JL, Richard C. Incidence and prognostic value of right ventricular failure in acute respiratory distress syndrome. Intensive Care Med 2009, 35:69-76. 10.1007/s00134-008-1307-1, 18839137.
24. Vieillard-Baron A, Schmitt JM, Augarde R, Fellahi JL, Prin S, Page B, Beauchet A, Jardin F. Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: incidence, clinical implications, and prognosis. Crit Care Med 2001, 29:1551-1555. 10.1097/00003246-200108000-00009, 11505125.
25. Vieillard-Baron A, Page B, Augarde R, Prin S, Qanadli S, Beauchet A, Dubourg O, Jardin F. Acute cor pulmonale in massive pulmonary embolism: incidence, echocardiographic pattern, clinical implications and recovery rate. Intensive Care Med 2001, 27:1481-1486. 10.1007/s001340101032, 11685341.
26. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, Johnsson H, Jorfeldt L. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J 1997, 134:479-487. 10.1016/S0002-8703(97)70085-1, 9327706.
27. Kasper W, Konstantinides S, Geibel A, Tiede N, Krause T, Just H. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997, 77:346-349. 484729, 9155614.
28. Clowes GH, Farrington GH, Zuschneid W, Cossette GR, Saravis C. Circulating factors in the etiology of pulmonary insufficiency and right heart failure accompanying severe sepsis (peritonitis). Ann Surg 1970, 171:663-678. 10.1097/00000658-197005000-00005, 1396815, 5441362.
29. Monchi M, Bellenfant F, Cariou A, Joly LM, Thebert D, Laurent I, Dhainaut JF, Brunet F. Early predictive factors of survival in the acute respiratory distress syndrome: a multivariate analysis. Am J Respir Crit Care Med 1998, 158:1076-1081.
30. Squara P, Dhainaut JF, Artigas A, Carlet J. Hemodynamic profile in severe ARDS: results of the European Collaborative ARDS Study. Intensive Care Med 1998, 24:1018-1028. 10.1007/s001340050710, 9840234.
31. Leeman M. Pulmonary hypertension in acute respiratory distress syndrome. Monaldi Arch Chest Dis 1999, 54:146-149.
32. Ramakrishna G, Sprung J, Ravi BS, Chandrasekaran K, McGoon MD. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. J Am Coll Cardiol 2005, 45:1691-1699. 10.1016/j.jacc.2005.02.055, 15893189.
33. Minai OA, Venkateshiah SB, Arroliga AC. Surgical intervention in patients with moderate to severe pulmonary arterial hypertension. Conn Med 2006, 70:239-243.
34. Lai HC, Lai HC, Wang KY, Lee WL, Ting CT, Liu TJ. Severe pulmonary hypertension complicates postoperative outcome of non-cardiac surgery. Br J Anaesth 2007, 99:184-190. 10.1093/bja/aem126, 17576968.
35. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000, 6:443-450. 10.1053/jlts.2000.6356, 10915166.
36. Price LC, Montani D, Jais X, Dick JR, Simonneau G, Sitbon O, Mercier FJ, Humbert M. Non-cardiothoracic non-obstetric surgery in mild-moderate pulmonary hypertension: perioperative management of 28 consecutive individual cases. Eur Respir J 2010, 35:1294-1302. 10.1183/09031936.00113009, 19897552.
37. Bonnin M, Mercier FJ, Sitbon O, Roger-Christoph S, Jais X, Humbert M, Audibert F, Frydman R, Simonneau G, Benhamou D. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology 2005, 102:1133-1137. discussion 1135A-1136A, 10.1097/00000542-200506000-00012, 15915025.
38. Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension?. Eur Heart J 2009, 30:256-265. 10.1093/eurheartj/ehn597, 19147605.
39. Bernstein AD, Parsonnet V. Bedside estimation of risk as an aid for decision-making in cardiac surgery. Ann Thorac Surg 2000, 69:823-828. 10.1016/S0003-4975(99)01424-1, 10750767.
40. Subramaniam K, Yared JP. Management of pulmonary hypertension in the operating room. Semin Cardiothorac Vasc Anesth 2007, 11:119-136. 10.1177/1089253207301733, 17536116.
41. Morgan JA, John R, Lee BJ, Oz MC, Naka Y. Is severe right ventricular failure in left ventricular assist device recipients a risk factor for unsuccessful bridging to transplant and post-transplant mortality. Ann Thorac Surg 2004, 77:859-863. 10.1016/j.athoracsur.2003.09.048, 14992887.
42. Price LC, Montani D, Jais X, Dick JR, Simonneau G, Sitbon O, Mercier FJ, Humbert M. Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension. Eur Respir J 35:1294-1302. 10.1183/09031936.00113009, 19897552.
43. McIntyre KM, Sasahara AA. Determinants of right ventricular function and hemodynamics after pulmonary embolism. Chest 1974, 65:534-543. 10.1378/chest.65.5.534, 4826027.
44. Kerbaul F, Rondelet B, Motte S, Fesler P, Hubloue I, Ewalenko P, Naeije R, Brimioulle S. Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2004, 32:1035-1040. 10.1097/01.CCM.0000120052.77953.07, 15071398.
45. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol 2004, 43:405-409. 10.1016/j.jacc.2003.09.036, 15013122.
46. Pinsky MR. Heart-lung interactions. Curr Opin Crit Care 2007, 13:528-531. 10.1097/MCC.0b013e3282efad97, 17762231.
47. Sibbald WJ, Driedger AA. Right ventricular function in acute disease states: pathophysiologic considerations. Crit Care Med 1983, 11:339-345. 10.1097/00003246-198305000-00004, 6340962.
48. Pinsky MR. Recent advances in the clinical application of heart-lung interactions. Curr Opin Crit Care 2002, 8:26-31. 10.1097/00075198-200202000-00005, 12205403.
49. Stojnic BB, Brecker SJ, Xiao HB, Helmy SM, Mbaissouroum M, Gibson DG. Left ventricular filling characteristics in pulmonary hypertension: a new mode of ventricular interaction. Br Heart J 1992, 68:16-20. 10.1136/hrt.68.7.16, 1024963, 1515286.
50. Taylor RR, Covell JW, Sonnenblick EH, Ross J. Dependence of ventricular distensibility on filling of the opposite ventricle. Am J Physiol 1967, 213:711-718.
51. Fellahi JL, Valtier B, Beauchet A, Bourdarias JP, Jardin F. Does positive end-expiratory pressure ventilation improve left ventricular function? A comparative study by transesophageal echocardiography in cardiac and noncardiac patients. Chest 1998, 114:556-562. 10.1378/chest.114.2.556, 9726745.
52. Louie EK, Lin SS, Reynertson SI, Brundage BH, Levitsky S, Rich S. Pressure and volume loading of the right ventricle have opposite effects on left ventricular ejection fraction. Circulation 1995, 92:819-824.
53. Louie EK, Rich S, Brundage BH. Doppler echocardiographic assessment of impaired left ventricular filling in patients with right ventricular pressure overload due to primary pulmonary hypertension. J Am Coll Cardiol 1986, 8:1298-1306. 10.1016/S0735-1097(86)80300-X, 3782636.
54. Ricciardi MJ, Bossone E, Bach DS, Armstrong WF, Rubenfire M. Echocardiographic predictors of an adverse response to a nifedipine trial in primary pulmonary hypertension: diminished left ventricular size and leftward ventricular septal bowing. Chest 1999, 116:1218-1223. 10.1378/chest.116.5.1218, 10559078.
55. Vlahakes GJ, Turley K, Hoffman JI. The pathophysiology of failure in acute right ventricular hypertension: hemodynamic and biochemical correlations. Circulation 1981, 63:87-95.
56. Weitzenblum E. Chronic cor pulmonale. Heart 2003, 89:225-230. 10.1136/heart.89.2.225, 1767533, 12527688.
57. Blaise G, Langleben D, Hubert B. Pulmonary arterial hypertension: pathophysiology and anesthetic approach. Anesthesiology 2003, 99:1415-1432. 10.1097/00000542-200312000-00027, 14639158.
58. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis 2005, 16:13-18. 10.1097/00019501-200502000-00003, 15654194.
59. Hadian M, Pinsky MR. Evidence-based review of the use of the pulmonary artery catheter impact data and complications. Crit Care 2006, 10 Suppl 3:S8. 10.1186/cc4834, 17164020.
60. Handa F, Kyo SE, Miyao H. Reduction in the use of pulmonary artery catheter for cardiovascular surgery. Masui 2003, 52:420-423.
61. Mebazaa A, Pitsis AA, Rudiger A, Toller W, Longrois D, Ricksten SE, Bobek I, De Hert S, Wieselthaler G, Schirmer U, von Segesser LK, Sander M, Poldermans D, Ranucci M, Karpati PC, Wouters P, Seeberger M, Schmid ER, Weder W, Follath F. Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. Crit Care 2010, 14:201. 10.1186/cc8153, 20497611.
62. Zapol WM, Kobayashi K, Snider MT, Greene R, Laver MB. Vascular obstruction causes pulmonary hypertension in severe acute respiratory failure. Chest 1977, 71:306-307.
63. Vieillard-Baron A. Assessment of right ventricular function. Curr Opin Crit Care 2009, 15:254-260. 10.1097/MCC.0b013e32832b70c9, 19451815.
64. Gadhinglajkar S, Sreedhar R, Jayakumar K, Misra M, Ganesh S, Panicker V. Intra-operative assessment of biventricular function using trans-esophageal echocardiography pre/post-pulmonary thromboembolectomy in patient with chronic thromboembolic pulmonary hypertension. Ann Card Anaesth 2009, 12:140-145. 10.4103/0971-9784.53449, 19602740.
65. Serra E, Feltracco P, Barbieri S, Forti A, Ori C. Transesophageal echocardiography during lung transplantation. Transplant Proc 2007, 39:1981-1982. 10.1016/j.transproceed.2007.05.004, 17692671.
66. Currie PJ, Seward JB, Chan KL, Fyfe DA, Hagler DJ, Mair DD, Reeder GS, Nishimura RA, Tajik AJ. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 1985, 6:750-756. 10.1016/S0735-1097(85)80477-0, 4031289.
67. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984, 70:657-662.
68. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000, 102:865-870.
69. Logeart D, Lecuyer L, Thabut G, Tabet JY, Tartiere JM, Chavelas C, Bonnin F, Stievenart JL, Solal AC. Biomarker-based strategy for screening right ventricular dysfunction in patients with non-massive pulmonary embolism. Intensive Care Med 2007, 33:286-292. 10.1007/s00134-006-0482-1, 17165016.
70. Lega JC, Lacasse Y, Lakhal L, Provencher S. Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis. Thorax 2009, 64:869-875. 10.1136/thx.2008.110965, 19525265.
71. Mehta NJ, Jani K, Khan IA. Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J 2003, 145:821-825. 10.1016/S0002-8703(02)94704-6, 12766738.
72. Clark BJ, Brown NJ, Moss M, Bull TM. Increased serum BNP concentrations are associated with pulmonary vascular dysfunction in patients with acute lung injury. Am J Respir Crit Care Med 2010, 181:A2582.
73. Alpert JS, Smith R, Carlson J, Ockene IS, Dexter L, Dalen JE. Mortality in patients treated for pulmonary embolism. JAMA 1976, 236:1477-1480. 10.1001/jama.236.13.1477, 989113.
74. Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, Taveira da Silva AM, Come PC, Lee RT, Parker JA. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993, 341:507-511. 10.1016/0140-6736(93)90274-K, 8094768.
75. Goldhaber SZ, Morpurgo M. Diagnosis, treatment, and prevention of pulmonary embolism: report of the WHO/International Society and Federation of Cardiology Task Force. JAMA 1992, 268:1727-1733. 10.1001/jama.268.13.1727, 1527883.
76. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004, 350:2257-2264. 10.1056/NEJMoa032274, 15163775.
77. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975, 17:259-270. 10.1016/S0033-0620(75)80017-X, 1089991.
78. Lualdi JC, Goldhaber SZ. Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors detection, and therapeutic implications. Am Heart J 1995, 130:1276-1282. 10.1016/0002-8703(95)90155-8, 7484782.
79. Bhorade S, Christenson J, O'Connor M, Lavoie A, Pohlman A, Hall JB. Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med 1999, 159:571-579.
80. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians?. BMJ 2008, 336:995-998. 10.1136/bmj.39490.551019.BE, 18456631.
81. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336:924-926. 10.1136/bmj.39489.470347.AD, 18436948.
82. Gan CT, Lankhaar JW, Marcus JT, Westerhof N, Marques KM, Bronzwaer JG, Boonstra A, Postmus PE, Vonk-Noordegraaf A. Impaired left ventricular filling due to right-to-left ventricular interaction in patients with pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 2006, 290:H1528-H1533.
83. Zamanian RT, Haddad F, Doyle RL, Weinacker AB. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 2007, 35:2037-2050. 10.1097/01.CCM.0000280433.74246.9E, 17855818.
84. Reuse C, Vincent JL, Pinsky MR. Measurements of right ventricular volumes during fluid challenge. Chest 1990, 98:1450-1454. 10.1378/chest.98.6.1450, 2245688.
85. Naeije R, Vachiery JL. Medical therapy of pulmonary hypertension conventional therapies. Clin Chest Med 2001, 22:517-527. 10.1016/S0272-5231(05)70288-4, 11590845.
86. Layish DT, Tapson VF. Pharmacologic hemodynamic support in massive pulmonary embolism. Chest 1997, 111:218-224. 10.1378/chest.111.1.218, 8996020.
87. James KB, Stelmach K, Armstrong R, Young JB, Fouad-Tarazi F. Plasma volume and outcome in pulmonary hypertension. Tex Heart Inst J 2003, 30:305-307. 307716, 14677741.
88. Mathru M, Venus B, Smith RA, Shirakawa Y, Sugiura A. Treatment of low cardiac output complicating acute pulmonary hypertension in normovolemic goats. Crit Care Med 1986, 14:120-124. 10.1097/00003246-198602000-00008, 3080271.
89. Molloy WD, Lee KY, Girling L, Schick U, Prewitt RM. Treatment of shock in a canine model of pulmonary embolism. Am Rev Respir Dis 1984, 130:870-874.
90. Ghignone M, Girling L, Prewitt RM. Volume expansion versus norepinephrine in treatment of a low cardiac output complicating an acute increase in right ventricular afterload in dogs. Anesthesiology 1984, 60:132-135. 10.1097/00000542-198402000-00009, 6198941.
91. Belenkie I, Dani R, Smith ER, Tyberg JV. Effects of volume loading during experimental acute pulmonary embolism. Circulation 1989, 80:178-188.
92. Mercat A, Diehl JL, Meyer G, Teboul JL, Sors H. Hemodynamic effects of fluid loading in acute massive pulmonary embolism. Crit Care Med 1999, 27:540-544. 10.1097/00003246-199903000-00032, 10199533.
93. Redl G, Germann P, Plattner H, Hammerle A. Right ventricular function in early septic shock states. Intensive Care Med 1993, 19:3-7. 10.1007/BF01709270, 8440795.
94. Schneider AJ, Teule GJ, Groeneveld AB, Nauta J, Heidendal GA, Thijs LG. Biventricular performance during volume loading in patients with early septic shock, with emphasis on the right ventricle: a combined hemodynamic and radionuclide study. Am Heart J 1988, 116:103-112. 10.1016/0002-8703(88)90256-6, 3394612.
95. Siva A, Shah AM. Moderate mitral stenosis in pregnancy: the haemodynamic impact of diuresis. Heart 2005, 91:e3. 10.1136/hrt.2004.053017, 1768646, 15604310.
96. Ducas J, Prewitt RM. Pathophysiology and therapy of right ventricular dysfunction due to pulmonary embolism. Cardiovasc Clin 1987, 17:191-202.
97. Mebazaa A, Karpati P, Renaud E, Algotsson L. Acute right ventricular failure: from pathophysiology to new treatments. Intensive Care Med 2004, 30:185-196. 10.1007/s00134-003-2025-3, 14618229.
98. Goldhaber SZ. The approach to massive pulmonary embolism. Semin Respir Crit Care Med 2000, 21:555-561. 10.1055/s-2000-13184, 16088764.
99. Forrest P. Anaesthesia and right ventricular failure. Anaesth Intensive Care 2009, 37:370-385.
100. Kwak YL, Lee CS, Park YH, Hong YW. The effect of phenylephrine and norepinephrine in patients with chronic pulmonary hypertension. Anaesthesia 2002, 57:9-14. 10.1046/j.1365-2044.2002.02324.x, 11843735.
101. Dunser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med 2009, 24:293-316. 10.1177/0885066609340519, 19703817.
102. Bergofsky EH. Humoral control of the pulmonary circulation. Annu Rev Physiol 1980, 42:221-233. 10.1146/annurev.ph.42.030180.001253, 6250452.
103. Hanson EL, O'Connor NE, Drinker PA. Hemodynamic response to controlled ventilation during hypoxia in man and animals. Surg Forum 1972, 23:207-209.
104. Tourneux P, Rakza T, Bouissou A, Krim G, Storme L. Pulmonary circulatory effects of norepinephrine in newborn infants with persistent pulmonary hypertension. J Pediatr 2008, 153:345-349. 10.1016/j.jpeds.2008.03.007, 18534241.
105. Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V, Bachetoni A, D'Alessandro M, Van Aken H, Pietropaoli P, Westphal M. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care 2009, 13:R130. 10.1186/cc7990, 2750187, 19664253.
106. Schreuder WO, Schneider AJ, Groeneveld AB, Thijs LG. Effect of dopamine vs norepinephrine on hemodynamics in septic shock: emphasis on right ventricular performance. Chest 1989, 95:1282-1288. 10.1378/chest.95.6.1282, 2721267.
107. Ducas J, Duval D, Dasilva H, Boiteau P, Prewitt RM. Treatment of canine pulmonary hypertension: effects of norepinephrine and isoproterenol on pulmonary vascular pressure-flow characteristics. Circulation 1987, 75:235-242.
108. Hirsch LJ, Rooney MW, Wat SS, Kleinmann B, Mathru M. Norepinephrine and phenylephrine effects on right ventricular function in experimental canine pulmonary embolism. Chest 1991, 100:796-801. 10.1378/chest.100.3.796, 1889275.
109. Martin C, Perrin G, Saux P, Papazian L, Gouin F. function Effects of norepinephrine on right ventricular in septic shock patients. Intensive Care Med 1994, 20:444-447. 10.1007/BF01710657, 7798451.
110. Bertolissi M, Bassi F, Da Broi U. Norepinephrine can be useful for the treatment of right ventricular failure combined with acute pulmonary hypertension and systemic hypotension: a case report. Minerva Anestesiol 2001, 67:79-84.
111. Rich S, Gubin S, Hart K. The effects of phenylephrine on right ventricular performance in patients with pulmonary hypertension. Chest 1990, 98:1102-1106. 10.1378/chest.98.5.1102, 2225953.
112. Eichinger MR, Walker BR. Enhanced pulmonary arterial dilation to arginine vasopressin in chronically hypoxic rats. Am J Physiol 1994, 267:H2413-H2419.
113. Walker BR, Haynes J, Wang HL, Voelkel NF. Vasopressin-induced pulmonary vasodilation in rats. Am J Physiol 1989, 257:H415-H422.
114. Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery: V1-receptor-mediated production of nitric oxide. Chest 1993, 103:1241-1245. 10.1378/chest.103.4.1241, 8131474.
115. Jeon Y, Ryu JH, Lim YJ, Kim CS, Bahk JH, Yoon SZ, Choi JY. Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients. Eur J Cardiothorac Surg 2006, 29:952-956. 10.1016/j.ejcts.2006.02.032, 16675238.
116. Tayama E, Ueda T, Shojima T, Akasu K, Oda T, Fukunaga S, Akashi H, Aoyagi S. Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. Interact Cardiovasc Thorac Surg 2007, 6:715-719. 10.1510/icvts.2007.159624, 17704123.
117. Braun EB, Palin CA, Hogue CW. Vasopressin during spinal anesthesia in a patient with primary pulmonary hypertension treated with intravenous epoprostenol. Anesth Analg 2004, 99:36-37. 10.1213/01.ANE.0000121349.15880.DC, 15281498.
118. Price LC, Forrest P, Sodhi V, Adamson DL, Nelson-Piercy C, Lucey M, Howard LS. Use of vasopressin after caesarean section in idiopathic pulmonary arterial hypertension. Br J Anaesth 2007, 99:552-555. 10.1093/bja/aem180, 17660458.
119. Smith AM, Elliot CM, Kiely DG, Channer KS. The role of vasopressin in cardiorespiratory arrest and pulmonary hypertension. QJM 2006, 99:127-133. 10.1093/qjmed/hcl009, 16467356.
120. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008, 358:877-887. 10.1056/NEJMoa067373, 18305265.
121. Torgersen C, Dunser MW, Wenzel V, Jochberger S, Mayr V, Schmittinger CA, Lorenz I, Schmid S, Westphal M, Grander W, Luckner G. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med 2010, 36:57-65. 10.1007/s00134-009-1630-1, 19756505.
122. Luckner G, Mayr VD, Jochberger S, Wenzel V, Ulmer H, Hasibeder WR, Dunser MW. Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med 2007, 35:2280-2285. 10.1097/01.CCM.0000281853.50661.23, 17944015.
123. Gold J, Cullinane S, Chen J, Seo S, Oz MC, Oliver JA, Landry DW. Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. Am J Cardiol 2000, 85:506-508. A511, 10.1016/S0002-9149(99)00783-3, 10728962.
124. Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997, 96:II-286-II-290.
125. Vida VL, Mack R, Castaneda AR. The role of vasopressin in treating systemic inflammatory syndrome complicated by right ventricular failure. Cardiol Young 2005, 15:88-90. 10.1017/S1047951105000193, 15831170.
126. Scheurer MA, Bradley SM, Atz AM. Vasopressin to attenuate pulmonary hypertension and improve systemic blood pressure after correction of obstructed total anomalous pulmonary venous return. J Thorac Cardiovasc Surg 2005, 129:464-466. 10.1016/j.jtcvs.2004.06.043, 15678072.
127. Wang HJ, Wong CS, Chiang CY, Yeh CC, Cherng CH, Ho ST, Wu CT. Low-dose vasopressin infusion can be an alternative in treating patients with refractory septic shock combined with chronic pulmonary hypertension: a case report. Acta Anaesthesiol Sin 2003, 41:77-80.
128. Jain RL, Horn EM. Peripheral vasodilation complicated by pulmonary hypertension: a role for vasopressin. Am J Respir Crit Care Med 2008, 177:A919.
129. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001, 27:1416-1421. 10.1007/s001340101014, 11511958.
130. Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003, 107:2313-2319. 10.1161/01.CIR.0000066692.71008.BB, 12732600.
131. Dunser MW, Mayr AJ, Stallinger A, Ulmer H, Ritsch N, Knotzer H, Pajk W, Mutz NJ, Hasibeder WR. Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med 2002, 28:746-751. 10.1007/s00134-002-1265-y, 12107681.
132. Lauzier F, Levy B, Lamarre P, Lesur O. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med 2006, 32:1782-1789. 10.1007/s00134-006-0378-0, 17019548.
133. Varma S, Jaju BP, Bhargava KP. Mechanism of vasopressin-induced bradycardia in dogs. Circ Res 1969, 24:787-792.
134. Naeije R, Hallemans R, Mols P, Melot C, Reding P. Effect of vasopressin and somatostatin on hemodynamics and blood gases in patients with liver cirrhosis. Crit Care Med 1982, 10:578-582. 10.1097/00003246-198209000-00004, 6125342.
135. Mols P, Hallemans R, Van Kuyk M, Melot C, Lejeune P, Ham H, Vertongen F, Naeije R. Hemodynamic effects of vasopressin, alone and in combination with nitroprusside, in patients with liver cirrhosis and portal hypertension. Ann Surg 1984, 199:176-181. 10.1097/00000658-198402000-00008, 1353329, 6696534.
136. Migotto WH, Dahi H. Effects of vasopressin on hemodynamics in cardiogenic shock. Chest 2005, 128:168S.
137. Walker BR, Childs ME, Adams EM. Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptors. Am J Physiol 1988, 255:H261-H265.
138. Leather HA, Segers P, Berends N, Vandermeersch E, Wouters PF. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med 2002, 30:2548-2552. 10.1097/00003246-200211000-00024, 12441768.
139. Indrambarya T, Boyd JH, Wang Y, McConechy M, Walley KR. Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice. Crit Care 2009, 13:R98. 10.1186/cc7930, 2717470, 19549333.
140. Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis 1995, 38:167-180. 10.1016/S0033-0620(05)80005-2, 7568905.
141. Holloway EL, Polumbo RA, Harrison DC. Acute circulatory effects of dopamine in patients with pulmonary hypertension. Br Heart J 1975, 37:482-485. 10.1136/hrt.37.5.482, 482825, 1137657.
142. Liet JM, Boscher C, Gras-Leguen C, Gournay V, Debillon T, Roze JC. Dopamine effects on pulmonary artery pressure in hypotensive preterm infants with patent ductus arteriosus. J Pediatr 2002, 140:373-375. 10.1067/mpd.2002.123100, 11953739.
143. Leier CV, Heban PT, Huss P, Bush CA, Lewis RP. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 1978, 58:466-475.
144. Lejeune P, Naeije R, Leeman M, Melot C, Deloof T, Delcroix M. Effects of dopamine and dobutamine on hyperoxic and hypoxic pulmonary vascular tone in dogs. Am Rev Respir Dis 1987, 136:29-35.
145. Schreuder WO, Schneider AJ, Groeneveld AB, Thijs LG. The influence of catecholamines on right ventricular function in septic shock. Intensive Care Med 1988, 14 Suppl 2:492-495.
146. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010, 362:779-789. 10.1056/NEJMoa0907118, 20200382.
147. Barrington KJ, Finer NN, Chan WK. A blind, randomized comparison of the circulatory effects of dopamine and epinephrine infusions in the newborn piglet during normoxia and hypoxia. Crit Care Med 1995, 23:740-748. 10.1097/00003246-199504000-00024, 7712765.
148. Stobierska-Dzierzek B, Awad H, Michler RE. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 2001, 38:923-931. 10.1016/S0735-1097(01)01486-3, 11583860.
149. Prielipp RC, McLean R, Rosenthal MH, Pearl RG. Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension. Crit Care Med 1991, 19:60-67. 10.1097/00003246-199101000-00016, 1986891.
150. Acosta F, Sansano T, Palenciano CG, Falcon L, Domenech P, Robles R, Bueno FS, Ramirez P, Parrilla P. Effects of dobutamine on right ventricular function and pulmonary circulation in pulmonary hypertension during liver transplantation. Transplant Proc 2005, 37:3869-3870. 10.1016/j.transproceed.2005.10.045, 16386567.
151. Ferrario M, Poli A, Previtali M, Lanzarini L, Fetiveau R, Diotallevi P, Mussini A, Montemartini C. Hemodynamics of volume loading compared with dobutamine in severe right ventricular infarction. Am J Cardiol 1994, 74:329-333. 10.1016/0002-9149(94)90398-0, 8059693.
152. Sztrymf B, Souza R, Bertoletti L, Jais X, Sitbon O, Price LC, Simonneau G, Humbert M. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J 2010, 35:1286-1293. 10.1183/09031936.00070209, 19897557.
153. Vizza CD, Rocca GD, Roma AD, Iacoboni C, Pierconti F, Venuta F, Rendina E, Schmid G, Pietropaoli P, Fedele F. Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. Crit Care 2001, 5:355-361. 10.1186/cc1069, 96124, 11737925.
154. Pagnamenta A, Fesler P, Vandinivit A, Brimioulle S, Naeije R. Pulmonary vascular effects of dobutamine in experimental pulmonary hypertension. Crit Care Med 2003, 31:1140-1146. 10.1097/01.CCM.0000060126.75746.32, 12682485.
155. Bradford KK, Deb B, Pearl RG. Combination therapy with inhaled nitric oxide and intravenous dobutamine during pulmonary hypertension in the rabbit. J Cardiovasc Pharmacol 2000, 36:146-151. 10.1097/00005344-200008000-00002, 10942154.
156. Honerjager P. Pharmacology of bipyridine phosphodiesterase III inhibitors. Am Heart J 1991, 121:1939-1944. 10.1016/0002-8703(91)90828-6, 1852089.
157. Young RA, Ward A. Milrinone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 1988, 36:158-192. 10.2165/00003495-198836020-00003, 3053125.
158. Alousi AA, Johnson DC. Pharmacology of the bipyridines: amrinone and milrinone. Circulation 1986, 73:III10-III24.
159. Farah AE, Frangakis CJ. Studies on the mechanism of action of the bipyridine milrinone on the heart. Basic Res Cardiol 1989, 84 Suppl 1:85-103. 10.1007/BF02650349, 2554875.
160. Oztekin I, Yazici S, Oztekin DS, Goksel O, Issever H, Canik S. Effects of low-dose milrinone on weaning from cardiopulmonary bypass and after in patients with mitral stenosis and pulmonary hypertension. Yakugaku Zasshi 2007, 127:375-383. 10.1248/yakushi.127.375, 17268158.
161. Kihara S, Kawai A, Fukuda T, Yamamoto N, Aomi S, Nishida H, Endo M, Koyanagi H. Effects of milrinone for right ventricular failure after left ventricular assist device implantation. Heart Vessels 2002, 16:69-71. 10.1007/s380-002-8320-z, 11833845.
162. Fukazawa K, Poliac LC, Pretto EA. Rapid assessment and safe management of severe pulmonary hypertension with milrinone during orthotopic liver transplantation. Clin Transplant 2010, 24:515-519. 10.1111/j.1399-0012.2009.01119.x, 20002632.
163. Harris MN, Daborn AK, O'Dwyer JP. Milrinone and the pulmonary vascular system. Eur J Anaesthesiol Suppl 1992, 5:27-30.
164. Eichhorn EJ, Konstam MA, Weiland DS, Roberts DJ, Martin TT, Stransky NB, Salem DN. Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1987, 60:1329-1333. 10.1016/0002-9149(87)90616-3, 3687783.
165. Boldt J, Knothe C, Zickmann B, Ballesteros M, Russ W, Dapper F, Hempelmann G. The role of enoximone in cardiac surgery. Br J Anaesth 1992, 69:45-50. 10.1093/bja/69.1.45, 1386223.
166. Tarr TJ, Jeffrey RR, Kent AP, Cowen ME. Use of enoximone in weaning from cardiopulmonary bypass following mitral valve surgery. Cardiology 1990, 77 Suppl 3:51-57. discussion 62-67, 10.1159/000174672, 2148281.
167. Leeman M, Lejeune P, Melot C, Naeije R. Reduction in pulmonary hypertension and in airway resistances by enoximone (MDL 17,043) in decompensated COPD. Chest 1987, 91:662-666. 10.1378/chest.91.5.662, 2952467.
168. Jenkins IR, Dolman J, O'Connor JP, Ansley DM. Amrinone versus dobutamine in cardiac surgical patients with severe pulmonary hypertension after cardiopulmonary bypass: a prospective, randomized double-blinded trial. Anaesth Intensive Care 1997, 25:245-249.
169. Dupuis JY, Bondy R, Cattran C, Nathan HJ, Wynands JE. Amrinone and dobutamine as primary treatment of low cardiac output syndrome following coronary artery surgery: a comparison of their effects on hemodynamics and outcome. J Cardiothorac Vasc Anesth 1992, 6:542-553. 10.1016/1053-0770(92)90096-P, 1421065.
170. Hachenberg T, Mollhoff T, Holst D, Hammel D, Brussel T. Cardiopulmonary effects of enoximone or dobutamine and nitroglycerin on mitral valve regurgitation and pulmonary venous hypertension. J Cardiothorac Vasc Anesth 1997, 11:453-457. 10.1016/S1053-0770(97)90054-9, 9187994.
171. Ansell J, Tiarks C, McCue J, Parrilla N, Benotti JR. Amrinone-induced thrombocytopenia. Arch Intern Med 1984, 144:949-952. 10.1001/archinte.144.5.949, 6712412.
172. Boldt J, Knothe C, Zickmann B, Herold C, Dapper E, Hempelmann G. Phosphodiesterase-inhibitors enoximone and piroximone in cardiac surgery: influence on platelet count and function. Intensive Care Med 1992, 18:449-454. 10.1007/BF01708579, 1289367.
173. Kikura M, Lee MK, Safon RA, Bailey JM, Levy JH. The effects of milrinone on platelets in patients undergoing cardiac surgery. Anesth Analg 1995, 81:44-48. 10.1097/00000539-199507000-00009, 7598280.
174. Levy JH, Bailey JM, Deeb GM. Intravenous milrinone in cardiac surgery. Ann Thorac Surg 2002, 73:325-330. 10.1016/S0003-4975(01)02719-9, 11834047.
175. Chen EP, Bittner HB, Davis RD, Van Trigt P. Milrinone improves pulmonary hemodynamics and right ventricular function in chronic pulmonary hypertension. Ann Thorac Surg 1997, 63:814-821. 10.1016/S0003-4975(97)00011-8, 9066407.
176. Buckley MS, Feldman JP. Nebulized milrinone use in a pulmonary hypertensive crisis. Pharmacotherapy 2007, 27:1763-1766. 10.1592/phco.27.12.1763, 18041894.
177. Wang H, Gong M, Zhou B, Dai A. Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. Adv Ther 2009, 26:462-468. 10.1007/s12325-009-0019-4, 19381522.
178. Haraldssons A, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 2001, 93:1439-1445. table of contents, 10.1097/00000539-200112000-00018, 11726420.
179. Sablotzki A, Starzmann W, Scheubel R, Grond S, Czeslick EG. Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates. Can J Anaesth 2005, 52:1076-1082. 10.1007/BF03021608, 16326679.
180. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002, 360:196-202. 10.1016/S0140-6736(02)09455-2, 12133653.
181. Barraud D, Faivre V, Damy T, Welschbillig S, Gayat E, Heymes C, Payen D, Shah AM, Mebazaa A. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone. Crit Care Med 2007, 35:1376-1382. 10.1097/01.CCM.0000261889.18102.84, 17414729.
182. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, Lehikoinen P, Nagren K, Lehtonen L, Voipio-Pulkki LM. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000, 68:522-531. 10.1067/mcp.2000.110972, 11103755.
183. Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehikoinen P, Nagren K, Lehtonen L, Voipio-Pulkki LM. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 1997, 61:596-607. 10.1016/S0009-9236(97)90139-9, 9164421.
184. Yildiz O. Vasodilating mechanisms of levosimendan: involvement of K+ channels. J Pharmacol Sci 2007, 104:1-5. 10.1254/jphs.CP0060010, 17452812.
185. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure: study investigators. Circulation 2000, 102:2222-2227.
186. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002, 40:465-471.
187. Leather HA, Ver Eycken K, Segers P, Herijgers P, Vandermeersch E, Wouters PF. Effects of levosimendan on right ventricular function and ventriculovascular coupling in open chest pigs. Crit Care Med 2003, 31:2339-2343. 10.1097/01.CCM.0000084844.95073.C0, 14501965.
188. Kerbaul F, Rondelet B, Demester JP, Fesler P, Huez S, Naeije R, Brimioulle S. Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2006, 34:2814-2819. 10.1097/01.CCM.0000242157.19347.50, 16971854.
189. Missant C, Rex S, Segers P, Wouters PF. Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction. Crit Care Med 2007, 35:707-715. 10.1097/01.CCM.0000257326.96342.57, 17255859.
190. Duygu H, Ozerkan F, Zoghi M, Nalbantgil S, Yildiz A, Akilli A, Akin M, Nazli C, Ergene O. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure. Int J Clin Pract 2008, 62:228-233. 10.1111/j.1742-1241.2007.01510.x, 17949428.
191. Russ MA, Prondzinsky R, Carter JM, Schlitt A, Ebelt H, Schmidt H, Lemm H, Heinroth K, Soeffker G, Winkler M, Werdan K, Buerke M. Right ventricular function in myocardial infarction complicated by cardiogenic shock: improvement with levosimendan. Crit Care Med 2009, 37:3017-3023. 10.1097/CCM.0b013e3181b0314a, 19661807.
192. Yilmaz MB, Yontar C, Erdem A, Karadas F, Yalta K, Turgut OO, Yilmaz A, Tandogan I. Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure. Heart Vessels 2009, 24:16-21. 10.1007/s00380-008-1077-2, 19165563.
193. Poelzl G, Zwick RH, Grander W, Metzler B, Jonetzko P, Frick M, Ulmer H, Pachinger O, Roithinger FX. Safety and effectiveness of levosimendan in patients with predominant right heart failure. Herz 2008, 33:368-373. 10.1007/s00059-008-3051-2, 18773157.
194. Parissis JT, Paraskevaidis I, Bistola V, Farmakis D, Panou F, Kourea K, Nikolaou M, Filippatos G, Kremastinos D. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol 2006, 98:1489-1492. 10.1016/j.amjcard.2006.06.052, 17126656.
195. Morelli A, Teboul JL, Maggiore SM, Vieillard-Baron A, Rocco M, Conti G, De Gaetano A, Picchini U, Orecchioni A, Carbone I, Tritapepe L, Pietropaoli P, Westphal M. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med 2006, 34:2287-2293. 10.1097/01.CCM.0000230244.17174.4F, 16791109.
196. Morais RJ. Levosimendan in severe right ventricular failure following mitral valve replacement. J Cardiothorac Vasc Anesth 2006, 20:82-84. 10.1053/j.jvca.2005.01.039, 16458221.
197. Cicekcioglu F, Parlar AI, Ersoy O, Yay K, Hijazi A, Katircioglu SF. Levosimendan and severe pulmonary hypertension during open heart surgery. Gen Thorac Cardiovasc Surg 2008, 56:563-565. 10.1007/s11748-008-0301-4, 19002758.
198. Kleber FX, Bollmann T, Borst MM, Costard-Jackle A, Ewert R, Kivikko M, Petterson T, Pohjanjousi P, Sonntag S, Wikstrom G. Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study. J Clin Pharmacol 2009, 49:109-115.
199. Raper R. FMM: The heart and circulation in sepsis. Balliere's Clin Anaesthesiol 1990, 4:333-355.
200. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004, 351:1425-1436. 10.1056/NEJMra040291, 15459304.
201. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009, 34:1219-1263. 10.1183/09031936.00139009, 19749199.
202. Kieler-Jensen N, Lundin S, Ricksten SE. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside. J Heart Lung Transplant 1995, 14:436-443.
203. Creagh-Brown BC, Griffiths MJ, Evans TW. Bench-to-bedside review: inhaled nitric oxide therapy in adults. Crit Care 2009, 13:221. 10.1186/cc7734, 2717403, 19519946.
204. McNeil K, Dunning J, Morrell NW. The pulmonary physician in critical care, 13: the pulmonary circulation and right ventricular failure in the ITU. Thorax 2003, 58:157-162. 10.1136/thorax.58.2.157, 1746562, 12554902.
205. Channick RN, Hoch RC, Newhart JW, Johnson FW, Smith CM. Improvement in pulmonary hypertension and hypoxemia during nitric oxide inhalation in a patient with end-stage pulmonary fibrosis. Am J Respir Crit Care Med 1994, 149:811-814.
206. Griffiths MJ, Evans TW. Inhaled nitric oxide therapy in adults. N Engl J Med 2005, 353:2683-2695. 10.1056/NEJMra051884, 16371634.
207. Aranda M, Bradford KK, Pearl RG. Combined therapy with inhaled nitric oxide and intravenous vasodilators during acute and chronic experimental pulmonary hypertension. Anesth Analg 1999, 89:152-158. 10.1097/00000539-199907000-00027, 10389795.
208. Morgan JM, McCormack DG, Griffiths MJ, Morgan CJ, Barnes PJ, Evans TW. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation 1991, 84:1145-1149.
209. Fullerton DA, Jones SD, Grover FL, McIntyre RC. Adenosine effectively controls pulmonary hypertension after cardiac operations. Ann Thorac Surg 1996, 61:1118-1123. discussion 1123-1114, 10.1016/0003-4975(95)01149-8, 8607668.
210. Haywood GA, Sneddon JF, Bashir Y, Jennison SH, Gray HH, McKenna WJ. Adenosine infusion for the reversal of pulmonary vasoconstriction in biventricular failure: a good test but a poor therapy. Circulation 1992, 86:896-902.
211. Oliveira EC, Ribeiro AL, Amaral CF. Adenosine for vasoreactivity testing in pulmonary hypertension: a head-to-head comparison with inhaled nitric oxide. Respir Med 104:606-611. 10.1016/j.rmed.2009.11.010, 19962292.
212. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991, 338:1173-1174. 10.1016/0140-6736(91)92033-X, 1682593.
213. King R, Esmail M, Mahon S, Dingley J, Dwyer S. Use of nitric oxide for decompensated right ventricular failure and circulatory shock after cardiac arrest. Br J Anaesth 2000, 85:628-631. 10.1093/bja/85.4.628, 11064627.
214. Frostell CG, Blomqvist H, Hedenstierna G, Lundberg J, Zapol WM. Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation. Anesthesiology 1993, 78:427-435. 10.1097/00000542-199303000-00005, 8457043.
215. Schenk P, Mittermayer C, Ratheiser K. Inhaled nitric oxide in a patient with severe pulmonary embolism. Ann Emerg Med 1999, 33:710-714.
216. Capellier G, Jacques T, Balvay P, Blasco G, Belle E, Barale F. Inhaled nitric oxide in patients with pulmonary embolism. Intensive Care Med 1997, 23:1089-1092. 10.1007/s001340050461, 9407246.
217. Inglessis I, Shin JT, Lepore JJ, Palacios IF, Zapol WM, Bloch KD, Semigran MJ. Hemodynamic effects of inhaled nitric oxide in right ventricular myocardial infarction and cardiogenic shock. J Am Coll Cardiol 2004, 44:793-798. 10.1016/j.jacc.2004.05.047, 15312861.
218. Fujita Y, Nishida O, Sobue K, Ito H, Kusama N, Inagaki M, Katsuya H. Nitric oxide inhalation is useful in the management of right ventricular failure caused by myocardial infarction. Crit Care Med 2002, 30:1379-1381. 10.1097/00003246-200206000-00042, 12072697.
219. Rich GF, Murphy GD, Roos CM, Johns RA. Inhaled nitric oxide: selective pulmonary vasodilation in cardiac surgical patients. Anesthesiology 1993, 78:1028-1035. 10.1097/00000542-199306000-00004, 8512095.
220. Macdonald PS, Keogh A, Mundy J, Rogers P, Nicholson A, Harrison G, Jansz P, Kaan AM, Spratt P. Adjunctive use of inhaled nitric oxide during implantation of a left ventricular assist device. J Heart Lung Transplant 1998, 17:312-316.
221. Beck JR, Mongero LB, Kroslowitz RM, Choudhri AF, Chen JM, DeRose JJ, Argenziano M, Smerling AJ, Oz MC. Inhaled nitric oxide improves hemodynamics in patients with acute pulmonary hypertension after high-risk cardiac surgery. Perfusion 1999, 14:37-42.
222. Fernandez-Perez ER, Keegan MT, Harrison BA. Inhaled nitric oxide for acute right-ventricular dysfunction after extrapleural pneumonectomy. Respir Care 2006, 51:1172-1176.
223. Fattouch K, Sbraga F, Bianco G, Speziale G, Gucciardo M, Sampognaro R, Ruvolo G. Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. J Card Surg 2005, 20:171-176. 10.1111/j.0886-0440.2005.200383w.x, 15725144.
224. Takaba K, Aota M, Nonaka M, Sugimoto A, Konishi Y. Successful treatment of chronic thromboembolic pulmonary hypertension with inhaled nitric oxide after right ventricular thrombectomy. Jpn J Thorac Cardiovasc Surg 2004, 52:257-260. 10.1007/s11748-004-0120-1, 15195749.
225. Maxey TS, Smith CD, Kern JA, Tribble CG, Jones DR, Kron IL, Crosby IK. Beneficial effects of inhaled nitric oxide in adult cardiac surgical patients. Ann Thorac Surg 2002, 73:529-532. discussion 532-523, 10.1016/S0003-4975(01)03398-7, 11845869.
226. Khan TA, Schnickel G, Ross D, Bastani S, Laks H, Esmailian F, Marelli D, Beygui R, Shemin R, Watson L, Vartapetian I, Ardehali A. A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. J Thorac Cardiovasc Surg 2009, 138:1417-1424. 10.1016/j.jtcvs.2009.04.063, 19931670.
227. Carrier M, Blaise G, Belisle S, Perrault LP, Pellerin M, Petitclerc R, Pelletier LC. Nitric oxide inhalation in the treatment of primary graft failure following heart transplantation. J Heart Lung Transplant 1999, 18:664-667. 10.1016/S1053-2498(99)00025-X, 10452342.
228. Trummer G, Berchtold-Herz M, Martin J, Beyersdorf F. Successful treatment of pulmonary hypertension with inhaled nitric oxide after pulmonary embolectomy. Ann Thorac Surg 2002, 73:1299-1301. 10.1016/S0003-4975(01)03265-9, 11996278.
229. Yoshikawa T, Date H, Yamashita M, Nagahiro I, Aoe M, Shimizu N. Inhaled nitric oxide ameliorates postoperative acute graft dysfunction after living-donor lobar lung transplantation. Jpn J Thorac Cardiovasc Surg 2000, 48:742-745.
230. Girardis M, Pasqualotto A, Colo F, Dal Pos L, Sabbadini D, Pasqualucci A, Pasetto A. Severe hypoxemia and pulmonary hypertension during orthotopic liver transplantation: a successful use of inhaled nitric oxide. Intensive Care Med 1999, 25:638. 10.1007/s001340050919, 10416922.
231. Ralley FE. The use of nitric oxide for managing catastrophic pulmonary vasoconstriction arising from protamine administration. Anesth Analg 1999, 88:505-507. 10.1097/00000539-199903000-00007, 10071995.
232. Williams TJ, Salamonsen RF, Snell G, Kaye D, Esmore DS. Preliminary experience with inhaled nitric oxide for acute pulmonary hypertension after heart transplantation. J Heart Lung Transplant 1995, 14:419-423.
233. Molmenti EP, Ramsay M, Ramsay K, Lynch K, Tillmann Hein HA, Molmenti H, Levy M, Goldstein R, Ausloos K, East C, Fasola C, Jung G, Escobar J, Klintmalm G. Epoprostenol and nitric oxide therapy for severe pulmonary hypertension in liver transplantation. Transplant Proc 2001, 33:1332. 10.1016/S0041-1345(00)02807-4, 11267313.
234. Snow DJ, Gray SJ, Ghosh S, Foubert L, Oduro A, Higenbottam TW, Wells FC, Latimer RD. Inhaled nitric oxide in patients with normal and increased pulmonary vascular resistance after cardiac surgery. Br J Anaesth 1994, 72:185-189. 10.1093/bja/72.2.185, 8110572.
235. Bender KA, Alexander JA, Enos JM, Skimming JW. Effects of inhaled nitric oxide in patients with hypoxemia and pulmonary hypertension after cardiac surgery. Am J Crit Care 1997, 6:127-131.
236. Solina A, Papp D, Ginsberg S, Krause T, Grubb W, Scholz P, Pena LL, Cody R. A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. J Cardiothorac Vasc Anesth 2000, 14:12-17. 10.1016/S1053-0770(00)90048-X, 10698385.
237. Solina AR, Ginsberg SH, Papp D, Pantin EJ, Denny J, Ghandivel I, Krause TJ. Response to nitric oxide during adult cardiac surgery. J Invest Surg 2002, 15:5-14. 10.1080/08941930252807732, 11931495.
238. Solina AR, Ginsberg SH, Papp D, Grubb WR, Scholz PM, Pantin EJ, Cody RP, Krause TJ. Dose response to nitric oxide in adult cardiac surgery patients. J Clin Anesth 2001, 13:281-286. 10.1016/S0952-8180(01)00270-7, 11435053.
239. Fattouch K, Sbraga F, Sampognaro R, Bianco G, Gucciardo M, Lavalle C, Vizza CD, Fedele F, Ruvolo G. Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind study. J Cardiovasc Med (Hagerstown) 2006, 7:119-123. 10.2459/01.JCM.0000203850.97890.fe, 16645371.
240. Healy DG, Veerasingam D, McHale J, Luke D. Successful perioperative utilisation of inhaled nitric oxide in mitral valve surgery. J Cardiovasc Surg (Torino) 2006, 47:217-220.
241. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993, 328:399-405. 10.1056/NEJM199302113280605, 8357359.
242. Fierobe L, Brunet F, Dhainaut JF, Monchi M, Belghith M, Mira JP, Dall'ava-Santucci J, Dinh-Xuan AT. Effect of inhaled nitric oxide on right ventricular function in adult respiratory distress syndrome. Am J Respir Crit Care Med 1995, 151:1414-1419.
243. Romberg-Camps MJ, Korsten HH, Botman CJ, Bindels AJ, Roos AN. Right ventricular failure in acute respiratory distress syndrome. Neth J Med 2000, 57:94-97. 10.1016/S0300-2977(00)00052-8, 10978554.
244. Chiche JD, Canivet JL, Damas P, Joris J, Lamy M. Inhaled nitric oxide for hemodynamic support after postpneumonectomy ARDS. Intensive Care Med 1995, 21:675-678. 10.1007/BF01711547, 8522673.
245. Benzing A, Mols G, Beyer U, Geiger K. Large increase in cardiac output in a patient with ARDS and acute right heart failure during inhalation of nitric oxide. Acta Anaesthesiol Scand 1997, 41:643-646. 10.1111/j.1399-6576.1997.tb04758.x, 9181169.
246. Bigatello LM, Hurford WE, Kacmarek RM, Roberts JD, Zapol WM. Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome: effects on pulmonary hemodynamics and oxygenation. Anesthesiology 1994, 80:761-770. 10.1097/00000542-199404000-00007, 8024129.
247. Hsu CW, Lee DL, Lin SL, Sun SF, Chang HW. The initial response to inhaled nitric oxide treatment for intensive care unit patients with acute respiratory distress syndrome. Respiration 2008, 75:288-295. 10.1159/000101478, 17396026.
248. Gerlach H, Keh D, Semmerow A, Busch T, Lewandowski K, Pappert DM, Rossaint R, Falke KJ. Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study. Am J Respir Crit Care Med 2003, 167:1008-1015. 10.1164/rccm.2108121, 12663340.
249. Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, Hauser DL, Criner GJ, Davis K, Hyers TM, Papadakos P. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial: inhaled nitric oxide in ARDS study group. Crit Care Med 1998, 26:15-23. 10.1097/00003246-199801000-00011, 9428538.
250. Taylor RW, Zimmerman JL, Dellinger RP, Straube RC, Criner GJ, Davis K, Kelly KM, Smith TC, Small RJ. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA 2004, 291:1603-1609. 10.1001/jama.291.13.1603, 15069048.
251. Brett SJ, Hansell DM, Evans TW. Clinical correlates in acute lung injury: response to inhaled nitric oxide. Chest 1998, 114:1397-1404. 10.1378/chest.114.5.1397, 9824021.
252. Manktelow C, Bigatello LM, Hess D, Hurford WE. Physiologic determinants of the response to inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology 1997, 87:297-307. 10.1097/00000542-199708000-00017, 9286894.
253. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ 2007, 334:779. 10.1136/bmj.39139.716794.55, 1852043, 17383982.
254. Sokol J, Jacobs SE, Bohn D. Inhaled nitric oxide for acute hypoxic respiratory failure in children and adults: a meta-analysis. Anesth Analg 2003, 97:989-998. 10.1213/01.ANE.0000078819.48523.26, 14500146.
255. Troncy E, Collet JP, Shapiro S, Guimond JG, Blair L, Ducruet T, Francoeur M, Charbonneau M, Blaise G. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med 1998, 157:1483-1488.
256. Michael JR, Barton RG, Saffle JR, Mone M, Markewitz BA, Hillier K, Elstad MR, Campbell EJ, Troyer BE, Whatley RE, Liou TG, Samuelson WM, Carveth HJ, Hinson DM, Morris SE, Davis BL, Day RW. Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med 1998, 157:1372-1380.
257. Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study: the European Study Group of Inhaled Nitric Oxide. Intensive Care Med 1999, 25:911-919. 10.1007/s001340050982, 10501745.
258. Vater Y, Martay K, Dembo G, Bowdle TA, Weinbroum AA. Intraoperative epoprostenol and nitric oxide for severe pulmonary hypertension during orthotopic liver transplantation: a case report and review of the literature. Med Sci Monit 2006, 12:CS115-CS118.
259. Flondor M, Merkel M, Hofstetter C, Irlbeck M, Frey L, Zwissler B. The effect of inhaled nitric oxide and inhaled iloprost on hypoxaemia in a patient with pulmonary hypertension after pulmonary thrombarterectomy. Anaesthesia 2006, 61:1200-1203. 10.1111/j.1365-2044.2006.04861.x, 17090242.
260. Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, Semigran MJ. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005, 127:1647-1653. 10.1378/chest.127.5.1647, 15888841.
261. Lepore JJ, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM, Bloch KD, Semigran MJ. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002, 90:677-680. 10.1016/S0002-9149(02)02586-9, 12231108.
262. Lavoie A, Hall JB, Olson DM, Wylam ME. Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am J Respir Crit Care Med 1996, 153:1985-1987.
263. Atz AM, Adatia I, Wessel DL. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg 1996, 62:1759-1764. 10.1016/S0003-4975(96)00542-5, 8957383.
264. Christenson J, Lavoie A, O'Connor M, Bhorade S, Pohlman A, Hall JB. The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide. Am J Respir Crit Care Med 2000, 161:1443-1449.
265. Giacomini M, Borotto E, Bosotti L, Denkewitz T, Reali-Forster C, Carlucci P, Centanni S, Mantero A, Iapichino G. Vardenafil and weaning from inhaled nitric oxide: effect on pulmonary hypertension in ARDS. Anaesth Intensive Care 2007, 35:91-93.
266. Trachte AL, Lobato EB, Urdaneta F, Hess PJ, Klodell CT, Martin TD, Staples ED, Beaver TM. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg 2005, 79:194-197. discussion 194-197, 10.1016/j.athoracsur.2004.06.086, 15620942.
267. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999, 91:307-310. 10.1097/00000542-199907000-00041, 10422958.
268. Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 2006, 174:1042-1047. 10.1164/rccm.200605-694OC, 16917115.
269. Klodell CT, Morey TE, Lobato EB, Aranda JM, Staples ED, Schofield RS, Hess PJ, Martin TD, Beaver TM. Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg 2007, 83:68-71. discussion 71, 10.1016/j.athoracsur.2006.08.051, 17184632.
270. Mychaskiw G, Sachdev V, Heath BJ. Sildenafil (Viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular-assist device. J Clin Anesth 2001, 13:218-220. 10.1016/S0952-8180(01)00252-5, 11377161.
271. Moncada S, Gryglewski RJ, Bunting S, Vane JR. A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins 1976, 12:715-737. 10.1016/0090-6980(76)90048-4, 824686.
272. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002, 26:194-201.
273. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990, 112:485-491.
274. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jobsis MM, Blackburn DS, Shortino D, Crow JW. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334:296-302. 10.1056/NEJM199602013340504, 8532025.
275. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322-329. 10.1056/NEJMoa020204, 12151469.
276. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000, 342:1866-1870. 10.1056/NEJM200006223422503, 10861321.
277. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, Niedermeyer J, Fabel H, Seeger W. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension: German PPH study group. J Am Coll Cardiol 2000, 35:176-182. 10.1016/S0735-1097(99)00494-5, 10636277.
278. Olschewski H, Ghofrani HA, Walmrath D, Temmesfeld-Wollbruck B, Grimminger F, Seeger W. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Med 1998, 24:631-634. 10.1007/s001340050628, 9681789.
279. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002, 40:780-788. 10.1016/S0735-1097(02)02012-0, 12204511.
280. Kieler-Jensen N, Milocco I, Ricksten SE. Pulmonary vasodilation after heart transplantation: a comparison among prostacyclin, sodium nitroprusside, and nitroglycerin on right ventricular function and pulmonary selectivity. J Heart Lung Transplant 1993, 12:179-184.
281. D'Ambra MN, LaRaia PJ, Philbin DM, Watkins WD, Hilgenberg AD, Buckley MJ. Prostaglandin E1: a new therapy for refractory right heart failure and pulmonary hypertension after mitral valve replacement. J Thorac Cardiovasc Surg 1985, 89:567-572.
282. Vincent JL, Carlier E, Pinsky MR, Goldstein J, Naeije R, Lejeune P, Brimioulle S, Leclerc JL, Kahn RJ, Primo G. Prostaglandin E1 infusion for right ventricular failure after cardiac transplantation. J Thorac Cardiovasc Surg 1992, 103:33-39.
283. Radovancevic B, Vrtovec B, Thomas CD, Croitoru M, Myers TJ, Radovancevic R, Khan T, Massin EK, Frazier OH. Nitric oxide versus prostaglandin E1 for reduction of pulmonary hypertension in heart transplant candidates. J Heart Lung Transplant 2005, 24:690-695. 10.1016/j.healun.2004.04.016, 15949728.
284. Schmid ER, Burki C, Engel MH, Schmidlin D, Tornic M, Seifert B. Inhaled nitric oxide versus intravenous vasodilators in severe pulmonary hypertension after cardiac surgery. Anesth Analg 1999, 89:1108-1115. 10.1097/00000539-199911000-00007, 10553820.
285. Elliott CG, Palevsky HI. Treatment with epoprostenol of pulmonary arterial hypertension following mitral valve replacement for mitral stenosis. Thorax 2004, 59:536-537. 10.1136/thx.2003.008193, 1747029, 15170042.
286. Haraldsson A, Kieler-Jensen N, Ricksten SE. Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study. J Cardiothorac Vasc Anesth 1996, 10:864-868. 10.1016/S1053-0770(96)80047-4, 8969392.
287. Hache M, Denault AY, Belisle S, Couture P, Babin D, Tetrault F, Guimond JG. Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit. Can J Anaesth 2001, 48:924-929. 10.1007/BF03017361, 11606352.
288. De Wet CJ, Affleck DG, Jacobsohn E, Avidan MS, Tymkew H, Hill LL, Zanaboni PB, Moazami N, Smith JR. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg 2004, 127:1058-1067. 10.1016/j.jtcvs.2003.11.035, 15052203.
289. Schroeder RA, Wood GL, Plotkin JS, Kuo PC. Intraoperative use of inhaled PGI(2) for acute pulmonary hypertension and right ventricular failure. Anesth Analg 2000, 91:291-295. 10.1097/00000539-200008000-00008, 10910834.
290. Lowson SM, Doctor A, Walsh BK, Doorley PA. Inhaled prostacyclin for the treatment of pulmonary hypertension after cardiac surgery. Crit Care Med 2002, 30:2762-2764. 10.1097/00003246-200212000-00023, 12483070.
291. Kramm T, Eberle B, Guth S, Mayer E. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Eur J Cardiothorac Surg 2005, 28:882-888. 10.1016/j.ejcts.2005.09.007, 16242948.
292. Rex S, Schaelte G, Metzelder S, Flier S, de Waal EE, Autschbach R, Rossaint R, Buhre W. Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial. Acta Anaesthesiol Scand 2008, 52:65-72. 10.1111/j.1399-6576.2007.01476.x, 17976224.
293. Yurtseven N, Karaca P, Uysal G, Ozkul V, Cimen S, Tuygun AK, Yuksek A, Canik S. A comparison of the acute hemodynamic effects of inhaled nitroglycerin and iloprost in patients with pulmonary hypertension undergoing mitral valve surgery. Ann Thorac Cardiovasc Surg 2006, 12:319-323.
294. Baysal A, Bilsel S, Bulbul OG, Kayacioglu I, Idiz M, Yekeler I. Comparison of the usage of intravenous iloprost and nitroglycerin for pulmonary hypertension during valvular heart surgery. Heart Surg Forum 2006, 9:E536-E542. 10.1532/HSF98.20051161, 16387672.
295. Tissieres P, Nicod L, Barazzone-Argiroffo C, Rimensberger PC, Beghetti M. Aerosolized iloprost as a bridge to lung transplantation in a patient with cystic fibrosis and pulmonary hypertension. Ann Thorac Surg 2004, 78:e48-50. 10.1016/j.athoracsur.2003.12.096, 15337084.
296. Sablotzki A, Hentschel T, Gruenig E, Schubert S, Friedrich I, Muhling J, Dehne MG, Czeslick E. Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance. Eur J Cardiothorac Surg 2002, 22:746-752. 10.1016/S1010-7940(02)00488-8, 12414041.
297. Theodoraki K, Rellia P, Thanopoulos A, Tsourelis L, Zarkalis D, Sfyrakis P, Antoniou T. Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass. Can J Anaesth 2002, 49:963-967. 10.1007/BF03016884, 12419726.
298. Winterhalter M, Simon A, Fischer S, Rahe-Meyer N, Chamtzidou N, Hecker H, Zuk J, Piepenbrock S, Struber M. Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. J Cardiothorac Vasc Anesth 2008, 22:406-413. 10.1053/j.jvca.2007.10.015, 18503929.
299. Webb SA, Stott S, van Heerden PV. The use of inhaled aerosolized prostacyclin (IAP) in the treatment of pulmonary hypertension secondary to pulmonary embolism. Intensive Care Med 1996, 22:353-355. 10.1007/BF01700458, 8708174.
300. Haraldsson A, Kieler-Jensen N, Wadenvik H, Ricksten SE. Inhaled prostacyclin and platelet function after cardiac surgery and cardiopulmonary bypass. Intensive Care Med 2000, 26:188-194. 10.1007/s001340050044, 10784307.
301. Radermacher P, Santak B, Wust HJ, Tarnow J, Falke KJ. Prostacyclin and right ventricular function in patients with pulmonary hypertension associated with ARDS. Intensive Care Med 1990, 16:227-232. 10.1007/BF01705156, 2113542.
302. Zwissler B, Kemming G, Habler O, Kleen M, Merkel M, Haller M, Briegel J, Welte M, Peter K. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996, 154:1671-1677.
303. van Heerden PV, Barden A, Michalopoulos N, Bulsara MK, Roberts BL. Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest 2000, 117:819-827. 10.1378/chest.117.3.819, 10713012.
304. Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 1993, 342:961-962. 10.1016/0140-6736(93)92004-D, 8105216.
305. Van Heerden PV, Webb SA, Hee G, Corkeron M, Thompson WR. Inhaled aerosolized prostacyclin as a selective pulmonary vasodilator for the treatment of severe hypoxaemia. Anaesth Intensive Care 1996, 24:87-90.
306. Meyer J, Theilmeier G, Van Aken H, Bone HG, Busse H, Waurick R, Hinder F, Booke M. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesth Analg 1998, 86:753-758. 10.1097/00000539-199804000-00015, 9539597.
307. Kuhlen R, Walbert E, Frankel P, Thaden S, Behrendt W, Rossaint R. Combination of inhaled nitric oxide and intravenous prostacyclin for successful treatment of severe pulmonary hypertension in a patient with acute respiratory distress syndrome. Intensive Care Med 1999, 25:752-754. 10.1007/s001340050941, 10470582.
308. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000, 343:1342. 10.1056/NEJM200011023431814, 11183578.
309. Preston IR, Klinger JR, Houtches J, Nelson D, Farber HW, Hill NS. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respir Med 2005, 99:1501-1510. 10.1016/j.rmed.2005.03.026, 15890512.
310. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002, 105:2398-2403. 10.1161/01.CIR.0000016641.12984.DC, 12021227.
311. Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 2009, 361:1864-1871. 10.1056/NEJMct0904473, 19890129.
312. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995, 333:214-221. 10.1056/NEJM199507273330403, 7540722.
313. Black SM, Sanchez LS, Mata-Greenwood E, Bekker JM, Steinhorn RH, Fineman JR. sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001, 281:L1051-L1057.
314. Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, Phillips SC, Wilkins MR. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005, 172:105-113. 10.1164/rccm.200411-1587OC, 15817798.
315. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007, 116:238-248. 10.1161/CIRCULATIONAHA.106.655266, 17606845.
316. Packer M. Vasodilator therapy for primary pulmonary hypertension: limitations and hazards. Ann Intern Med 1985, 103:258-270.
317. De Santo LS, Mastroianni C, Romano G, Amarelli C, Marra C, Maiello C, Galdieri N, Della Corte A, Cotrufo M, Caianiello G. Role of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patients. Transplant Proc 2008, 40:2015-2018. 10.1016/j.transproceed.2008.05.055, 18675118.
318. Shim JK, Choi YS, Oh YJ, Kim DH, Hong YW, Kwak YL. Effect of oral sildenafil citrate on intraoperative hemodynamics in patients with pulmonary hypertension undergoing valvular heart surgery. J Thorac Cardiovasc Surg 2006, 132:1420-1425. 10.1016/j.jtcvs.2006.08.035, 17140970.
319. Madden BP, Sheth A, Ho TB, Park JE, Kanagasabay RR. Potential role for sildenafil in the management of perioperative pulmonary hypertension and right ventricular dysfunction after cardiac surgery. Br J Anaesth 2004, 93:155-156. 10.1093/bja/aeh571, 15192009.
320. Fung E, Fiscus RR, Yim AP, Angelini GD, Arifi AA. The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. Chest 2005, 128:3065-3073. 10.1378/chest.128.4.3065, 16236987.
321. Aubin MC, Laurendeau S, Mommerot A, Lamarche Y, Denault A, Carrier M, Perrault LP. Differential effects of inhaled and intravenous sildenafil in the prevention of the pulmonary endothelial dysfunction due to cardiopulmonary bypass. J Cardiovasc Pharmacol 2008, 51:11-17. 10.1097/FJC.0b013e3181598279, 18209563.
322. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002, 360:895-900. 10.1016/S0140-6736(02)11024-5, 12354470.
323. Ng J, Finney SJ, Shulman R, Bellingan GJ, Singer M, Glynne PA. Treatment of pulmonary hypertension in the general adult intensive care unit: a role for oral sildenafil?. Br J Anaesth 2005, 94:774-777. 10.1093/bja/aei114, 15764630.
324. Cornet AD, Hofstra JJ, Swart EL, Girbes AR, Juffermans NP. Sildenafil attenuates pulmonary arterial pressure but does not improve oxygenation during ARDS. Intensive Care Med 2010, 36:758-764. 10.1007/s00134-010-1754-3, 2850529, 20130830.
325. Botha P, Parry G, Dark JH, Macgowan GA. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. J Heart Lung Transplant 2009, 28:676-682. 10.1016/j.healun.2009.04.013, 19560695.
326. Moudgil R, Michelakis ED, Archer SL. Hypoxic pulmonary vasoconstriction. J Appl Physiol 2005, 98:390-403. 10.1152/japplphysiol.00733.2004, 15591309.
327. Lejeune P, Brimioulle S, Leeman M, Hallemans R, Melot C, Naeije R. Enhancement of hypoxic pulmonary vasoconstriction by metabolic acidosis in dogs. Anesthesiology 1990, 73:256-264. 10.1097/00000542-199008000-00012, 2166453.
328. Balanos GM, Talbot NP, Dorrington KL, Robbins PA. Human pulmonary vascular response to 4 h of hypercapnia and hypocapnia measured using Doppler echocardiography. J Appl Physiol 2003, 94:1543-1551.
329. Mekontso Dessap A, Charron C, Devaquet J, Aboab J, Jardin F, Brochard L, Vieillard-Baron A. Impact of acute hypercapnia and augmented positive end-expiratory pressure on right ventricle function in severe acute respiratory distress syndrome. Intensive Care Med 2009, 35:1850-1858. 10.1007/s00134-009-1569-2, 19652953.
330. Puybasset L, Stewart T, Rouby JJ, Cluzel P, Mourgeon E, Belin MF, Arthaud M, Landault C, Viars P. Inhaled nitric oxide reverses the increase in pulmonary vascular resistance induced by permissive hypercapnia in patients with acute respiratory distress syndrome. Anesthesiology 1994, 80:1254-1267. 10.1097/00000542-199406000-00013, 8010472.
331. Biondi JW, Schulman DS, Matthay RA. Effects of mechanical ventilation on right and left ventricular function. Clin Chest Med 1988, 9:55-71.
332. Jardin F, Gueret P, Dubourg O, Farcot JC, Margairaz A, Bourdarias JP. Two-dimensional echocardiographic evaluation of right ventricular size and contractility in acute respiratory failure. Crit Care Med 1985, 13:952-956. 10.1097/00003246-198511000-00035, 2932300.
333. Jardin F, Vieillard-Baron A. Is there a safe plateau pressure in ARDS? The right heart only knows. Intensive Care Med 2007, 33:444-447. 10.1007/s00134-007-0552-z, 17268795.
334. Vieillard-Baron A, Rabiller A, Chergui K, Peyrouset O, Page B, Beauchet A, Jardin F. Prone position improves mechanics and alveolar ventilation in acute respiratory distress syndrome. Intensive Care Med 2005, 31:220-226. 10.1007/s00134-004-2478-z, 15703898.
335. David M, von Bardeleben RS, Weiler N, Markstaller K, Scholz A, Karmrodt J, Eberle B. Cardiac function and haemodynamics during transition to high-frequency oscillatory ventilation. Eur J Anaesthesiol 2004, 21:944-952.
336. Gernoth C, Wagner G, Pelosi P, Luecke T. Respiratory and haemodynamic changes during decremental open lung positive end-expiratory pressure titration in patients with acute respiratory distress syndrome. Crit Care 2009, 13:R59. 10.1186/cc7786, 2689506, 19374751.
337. Shekerdemian LS, Shore DF, Lincoln C, Bush A, Redington AN. Negative-pressure ventilation improves cardiac output after right heart surgery. Circulation 1996, 94:II49-II55.
338. Shekerdemian LS, Bush A, Shore DF, Lincoln C, Redington AN. Cardiopulmonary interactions after Fontan operations: augmentation of cardiac output using negative pressure ventilation. Circulation 1997, 96:3934-3942.
339. Giesler GM, Gomez JS, Letsou G, Vooletich M, Smalling RW. Initial report of percutaneous right ventricular assist for right ventricular shock secondary to right ventricular infarction. Catheter Cardiovasc Interv 2006, 68:263-266. 10.1002/ccd.20846, 16819772.
340. Fonger JD, Borkon AM, Baumgartner WA, Achuff SC, Augustine S, Reitz BA. Acute right ventricular failure following heart transplantation: improvement with prostaglandin E1 and right ventricular assist. J Heart Transplant 1986, 5:317-321.
341. Nagarsheth NP, Pinney S, Bassily-Marcus A, Anyanwu A, Friedman L, Beilin Y. Successful placement of a right ventricular assist device for treatment of a presumed amniotic fluid embolism. Anesth Analg 2008, 107:962-964. 10.1213/ane.0b013e31817f10e8, 18713914.
342. Berman M, Tsui S, Vuylsteke A, Klein A, Jenkins DP. Life-threatening right ventricular failure in pulmonary hypertension: RVAD or ECMO?. J Heart Lung Transplant 2008, 27:1188-1189. 10.1016/j.healun.2008.07.017, 18926419.
343. Keogh AM, Mayer E, Benza RL, Corris P, Dartevelle PG, Frost AE, Kim NH, Lang IM, Pepke-Zaba J, Sandoval J. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol 2009, 54:S67-S77. 10.1016/j.jacc.2009.04.016, 19555860.
344. Strueber M, Hoeper MM, Fischer S, Cypel M, Warnecke G, Gottlieb J, Pierre A, Welte T, Haverich A, Simon AR, Keshavjee S. Bridge to thoracic organ transplantation in patients with pulmonary arterial hypertension using a pumpless lung assist device. Am J Transplant 2009, 9:853-857. 10.1111/j.1600-6143.2009.02549.x, 19344471.
345. Felton TW, McCormick BA, Finfer SR, Fisher MM. Life-threatening pulmonary hypertension and right ventricular failure complicating calcium and phosphate replacement in the intensive care unit. Anaesthesia 2006, 61:49-53. 10.1111/j.1365-2044.2005.04381.x, 16409342.
346. Satoh H, Masuda Y, Izuta S, Yaku H, Obara H. Pregnant patient with primary pulmonary hypertension: general anesthesia and extracorporeal membrane oxygenation support for termination of pregnancy. Anesthesiology 2002, 97:1638-1640. 10.1097/00000542-200212000-00045, 12459699.
347. Chan CY, Chen YS, Ko WJ, Wang SS, Chiu IS, Lee YC, Chu SH. Extracorporeal membrane oxygenation support for single lung transplantation in a patient with primary pulmonary hypertension. J Heart Lung Transplant 1998, 17:325-327.
348. Jones RL, St Cyr JA, Tornabene SP, Lauber B, Harken AH. Reversible pulmonary hypertension secondary to mitral valvular disease as an indication for extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth 1991, 5:494-497. 10.1016/1053-0770(91)90126-E, 1932654.
349. Gregoric ID, Chandra D, Myers TJ, Scheinin SA, Loyalka P, Kar B. Extracorporeal membrane oxygenation as a bridge to emergency heart-lung transplantation in a patient with idiopathic pulmonary arterial hypertension. J Heart Lung Transplant 2008, 27:466-468. 10.1016/j.healun.2008.01.016, 18374886.
350. Hsu HH, Ko WJ, Chen JS, Lin CH, Kuo SW, Huang SC, Lee YC. Extracorporeal membrane oxygenation in pulmonary crisis and primary graft dysfunction. J Heart Lung Transplant 2008, 27:233-237. 10.1016/j.healun.2007.11.570, 18267233.
351. Berman M, Tsui S, Vuylsteke A, Snell A, Colah S, Latimer R, Hall R, Arrowsmith JE, Kneeshaw J, Klein AA, Jenkins DP. Successful extracorporeal membrane oxygenation support after pulmonary thromboendarterectomy. Ann Thorac Surg 2008, 86:1261-1267. 10.1016/j.athoracsur.2008.06.037, 18805172.
352. Deehring R, Kiss AB, Garrett A, Hillier AG. Extracorporeal membrane oxygenation as a bridge to surgical embolectomy in acute fulminant pulmonary embolism. Am J Emerg Med 2006, 24:879-880. 10.1016/j.ajem.2006.03.009, 17098115.
353. Haller I, Kofler A, Lederer W, Chemelli A, Wiedermann FJ. Acute pulmonary artery embolism during transcatheter embolization: successful resuscitation with veno-arterial extracorporeal membrane oxygenation. Anesth Analg 2008, 107:945-947. 10.1213/ane.0b013e31817f91d8, 18713911.
354. Szocik J, Rudich S, Csete M. ECMO resuscitation after massive pulmonary embolism during liver transplantation. Anesthesiology 2002, 97:763-764. 10.1097/00000542-200209000-00059, 12218564.
355. Arlt M, Philipp A, Iesalnieks I, Kobuch R, Graf BM. Successful use of a new hand-held ECMO system in cardiopulmonary failure and bleeding shock after thrombolysis in massive post-partal pulmonary embolism. Perfusion 2009, 24:49-50. 10.1177/0267659109106295, 19567549.
356. Gold JP, Shemin RJ, DiSesa VJ, Cohn L, Collins JJ. Balloon pump support of the failing right heart. Clin Cardiol 1985, 8:599-602. 10.1002/clc.4960081110, 2933199.
357. Arafa OE, Geiran OR, Andersen K, Fosse E, Simonsen S, Svennevig JL. Intraaortic balloon pumping for predominantly right ventricular failure after heart transplantation. Ann Thorac Surg 2000, 70:1587-1593. 10.1016/S0003-4975(00)01864-6, 11093492.
358. Darrah WC, Sharpe MD, Guiraudon GM, Neal A. Intraaortic balloon counterpulsation improves right ventricular failure resulting from pressure overload. Ann Thorac Surg 1997, 64:1718-1723. discussion 1723-1714, 10.1016/S0003-4975(97)01102-8, 9436561.
359. Rothman A, Sklansky MS, Lucas VW, Kashani IA, Shaughnessy RD, Channick RN, Auger WR, Fedullo PF, Smith CM, Kriett JM, Jamieson SW. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 1999, 84:682-686. 10.1016/S0002-9149(99)00416-6, 10498139.
360. Rich S, Dodin E, McLaughlin VV. Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application. Am J Cardiol 1997, 80:369-371. 10.1016/S0002-9149(97)00370-6, 9264443.
361. Druml W, Steltzer H, Waldhausl W, Lenz K, Hammerle A, Vierhapper H, Gasic S, Wagner OF. Endothelin-1 in adult respiratory distress syndrome. Am Rev Respir Dis 1993, 148:1169-1173.
362. Lambermont B, Ghuysen A, Kolh P, Tchana-Sato V, Segers P, Gerard P, Morimont P, Magis D, Dogne JM, Masereel B, D'Orio V. Effects of endotoxic shock on right ventricular systolic function and mechanical efficiency. Cardiovasc Res 2003, 59:412-418. 10.1016/S0008-6363(03)00368-7, 12909324.
363. Nuckton TJ, Alonso JA, Kallet RH, Daniel BM, Pittet JF, Eisner MD, Matthay MA. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. N Engl J Med 2002, 346:1281-1286. 10.1056/NEJMoa012835, 11973365.
364. Marshall BE, Marshall C, Frasch F, Hanson CW. Role of hypoxic pulmonary vasoconstriction in pulmonary gas exchange and blood flow distribution. 1. Physiologic concepts. Intensive Care Med 1994, 20:291-297. 10.1007/BF01708968, 8046124.
365. Tomashefski JF, Davies P, Boggis C, Greene R, Zapol WM, Reid LM. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol 1983, 112:112-126. 1916312, 6859225.